Table 3.

Linear Multiple Regressions of MZ Intrapair Differences (Δ) in Metabolic Health Variables by Intrapair Differences in FMI, FFMI, and VO2max/FFM

Predictorβ95% CIPR2N
∆Fasting glucoseΔFMI0.20(0.01, 0.38)0.0420.09253
ΔFFMI0.05(−0.35, 0.45)0.816
ΔVO2max/FFM−0.02(−0.18, 0.14)0.820
∆HOMA-IRΔFMI0.59(0.22, 0.96)0.0020.28229
ΔFFMI−0.13(−0.42, 0.17)0.405
ΔVO2max/FFM−0.16(−0.33, 0.02)0.084
∆BIGTT-SIΔFMI−0.68(−0.87, −0.49)<0.0010.47224
ΔFFMI0.05(−0.13, 0.24)0.578
ΔVO2max/FFM0.17(−0.01, 0.36)0.068
∆BIGTT-AIRΔFMI0.48(0.18, 0.77)0.0010.25224
ΔFFMI0.01(−0.15, 0.17)0.947
ΔVO2max/FFM−0.08(−0.21, 0.04)0.196
∆Metabolic syndrome scoreΔFMI0.55(0.40, 0.70)<0.0010.39215
ΔFFMI0.08(−0.08, 0.24)0.333
ΔVO2max/FFM−0.09(−0.19, 0.01)0.083
∆Waist-to-height ratioΔFMI0.79(0.68, 0.89)<0.0010.85255
ΔFFMI0.19(0.12, 0.26)<0.001
ΔVO2max/FFM−0.03(−0.12, 0.06)0.458
∆Systolic blood pressureΔFMI0.36(0.15, 0.57)0.0010.13231
ΔFFMI−0.04(−0.23, 0.16)0.718
ΔVO2max/FFM0.04(−0.10, 0.17)0.608
∆Diastolic blood pressureΔFMI0.40(0.20, 0.59)<0.0010.13231
ΔFFMI−0.07(−0.34, 0.20)0.604
ΔVO2max/FFM0.04(−0.10, 0.19)0.554
∆LDLΔFMI0.47(0.28, 0.67)<0.0010.16243
ΔFFMI−0.18(−0.40, 0.04)0.103
ΔVO2max/FFM−0.10(−0.23, 0.03)0.119
∆HDLΔFMI−0.23(−0.60, 0.13)0.2050.14249
ΔFFMI−0.12(−0.30, 0.06)0.197
ΔVO2max/FFM0.13(0.03, 0.24)0.016
∆TriglyceridesΔFMI0.30(−0.03, 0.63)0.0770.11245
ΔFFMI0.02(−0.14, 0.18)0.834
ΔVO2max/FFM−0.04(−0.23, 0.16)0.718
∆Visceral fat volumeΔFMI0.98(0.86, 1.09)<0.0010.8541a
ΔFFMI−0.13(−0.27, 0.04)0.439
ΔVO2max/FFM−0.05(−0.21, 0.13)0.764
∆Liver fat %ΔFMI0.77(0.52, 0.98)<0.0010.5841a
ΔFFMI−0.11(−0.35, 0.17)0.504
ΔVO2max/FFM−0.16(−0.41, 0.12)0.335
Predictorβ95% CIPR2N
∆Fasting glucoseΔFMI0.20(0.01, 0.38)0.0420.09253
ΔFFMI0.05(−0.35, 0.45)0.816
ΔVO2max/FFM−0.02(−0.18, 0.14)0.820
∆HOMA-IRΔFMI0.59(0.22, 0.96)0.0020.28229
ΔFFMI−0.13(−0.42, 0.17)0.405
ΔVO2max/FFM−0.16(−0.33, 0.02)0.084
∆BIGTT-SIΔFMI−0.68(−0.87, −0.49)<0.0010.47224
ΔFFMI0.05(−0.13, 0.24)0.578
ΔVO2max/FFM0.17(−0.01, 0.36)0.068
∆BIGTT-AIRΔFMI0.48(0.18, 0.77)0.0010.25224
ΔFFMI0.01(−0.15, 0.17)0.947
ΔVO2max/FFM−0.08(−0.21, 0.04)0.196
∆Metabolic syndrome scoreΔFMI0.55(0.40, 0.70)<0.0010.39215
ΔFFMI0.08(−0.08, 0.24)0.333
ΔVO2max/FFM−0.09(−0.19, 0.01)0.083
∆Waist-to-height ratioΔFMI0.79(0.68, 0.89)<0.0010.85255
ΔFFMI0.19(0.12, 0.26)<0.001
ΔVO2max/FFM−0.03(−0.12, 0.06)0.458
∆Systolic blood pressureΔFMI0.36(0.15, 0.57)0.0010.13231
ΔFFMI−0.04(−0.23, 0.16)0.718
ΔVO2max/FFM0.04(−0.10, 0.17)0.608
∆Diastolic blood pressureΔFMI0.40(0.20, 0.59)<0.0010.13231
ΔFFMI−0.07(−0.34, 0.20)0.604
ΔVO2max/FFM0.04(−0.10, 0.19)0.554
∆LDLΔFMI0.47(0.28, 0.67)<0.0010.16243
ΔFFMI−0.18(−0.40, 0.04)0.103
ΔVO2max/FFM−0.10(−0.23, 0.03)0.119
∆HDLΔFMI−0.23(−0.60, 0.13)0.2050.14249
ΔFFMI−0.12(−0.30, 0.06)0.197
ΔVO2max/FFM0.13(0.03, 0.24)0.016
∆TriglyceridesΔFMI0.30(−0.03, 0.63)0.0770.11245
ΔFFMI0.02(−0.14, 0.18)0.834
ΔVO2max/FFM−0.04(−0.23, 0.16)0.718
∆Visceral fat volumeΔFMI0.98(0.86, 1.09)<0.0010.8541a
ΔFFMI−0.13(−0.27, 0.04)0.439
ΔVO2max/FFM−0.05(−0.21, 0.13)0.764
∆Liver fat %ΔFMI0.77(0.52, 0.98)<0.0010.5841a
ΔFFMI−0.11(−0.35, 0.17)0.504
ΔVO2max/FFM−0.16(−0.41, 0.12)0.335

Abbreviation: CI, confidence interval.

a

Subjects only from TwinFat. β denotes standardized regression coefficients, which correspond to how many standard deviations the outcome variable will change for an increase in the predictor of 1 standard deviation.

Table 3.

Linear Multiple Regressions of MZ Intrapair Differences (Δ) in Metabolic Health Variables by Intrapair Differences in FMI, FFMI, and VO2max/FFM

Predictorβ95% CIPR2N
∆Fasting glucoseΔFMI0.20(0.01, 0.38)0.0420.09253
ΔFFMI0.05(−0.35, 0.45)0.816
ΔVO2max/FFM−0.02(−0.18, 0.14)0.820
∆HOMA-IRΔFMI0.59(0.22, 0.96)0.0020.28229
ΔFFMI−0.13(−0.42, 0.17)0.405
ΔVO2max/FFM−0.16(−0.33, 0.02)0.084
∆BIGTT-SIΔFMI−0.68(−0.87, −0.49)<0.0010.47224
ΔFFMI0.05(−0.13, 0.24)0.578
ΔVO2max/FFM0.17(−0.01, 0.36)0.068
∆BIGTT-AIRΔFMI0.48(0.18, 0.77)0.0010.25224
ΔFFMI0.01(−0.15, 0.17)0.947
ΔVO2max/FFM−0.08(−0.21, 0.04)0.196
∆Metabolic syndrome scoreΔFMI0.55(0.40, 0.70)<0.0010.39215
ΔFFMI0.08(−0.08, 0.24)0.333
ΔVO2max/FFM−0.09(−0.19, 0.01)0.083
∆Waist-to-height ratioΔFMI0.79(0.68, 0.89)<0.0010.85255
ΔFFMI0.19(0.12, 0.26)<0.001
ΔVO2max/FFM−0.03(−0.12, 0.06)0.458
∆Systolic blood pressureΔFMI0.36(0.15, 0.57)0.0010.13231
ΔFFMI−0.04(−0.23, 0.16)0.718
ΔVO2max/FFM0.04(−0.10, 0.17)0.608
∆Diastolic blood pressureΔFMI0.40(0.20, 0.59)<0.0010.13231
ΔFFMI−0.07(−0.34, 0.20)0.604
ΔVO2max/FFM0.04(−0.10, 0.19)0.554
∆LDLΔFMI0.47(0.28, 0.67)<0.0010.16243
ΔFFMI−0.18(−0.40, 0.04)0.103
ΔVO2max/FFM−0.10(−0.23, 0.03)0.119
∆HDLΔFMI−0.23(−0.60, 0.13)0.2050.14249
ΔFFMI−0.12(−0.30, 0.06)0.197
ΔVO2max/FFM0.13(0.03, 0.24)0.016
∆TriglyceridesΔFMI0.30(−0.03, 0.63)0.0770.11245
ΔFFMI0.02(−0.14, 0.18)0.834
ΔVO2max/FFM−0.04(−0.23, 0.16)0.718
∆Visceral fat volumeΔFMI0.98(0.86, 1.09)<0.0010.8541a
ΔFFMI−0.13(−0.27, 0.04)0.439
ΔVO2max/FFM−0.05(−0.21, 0.13)0.764
∆Liver fat %ΔFMI0.77(0.52, 0.98)<0.0010.5841a
ΔFFMI−0.11(−0.35, 0.17)0.504
ΔVO2max/FFM−0.16(−0.41, 0.12)0.335
Predictorβ95% CIPR2N
∆Fasting glucoseΔFMI0.20(0.01, 0.38)0.0420.09253
ΔFFMI0.05(−0.35, 0.45)0.816
ΔVO2max/FFM−0.02(−0.18, 0.14)0.820
∆HOMA-IRΔFMI0.59(0.22, 0.96)0.0020.28229
ΔFFMI−0.13(−0.42, 0.17)0.405
ΔVO2max/FFM−0.16(−0.33, 0.02)0.084
∆BIGTT-SIΔFMI−0.68(−0.87, −0.49)<0.0010.47224
ΔFFMI0.05(−0.13, 0.24)0.578
ΔVO2max/FFM0.17(−0.01, 0.36)0.068
∆BIGTT-AIRΔFMI0.48(0.18, 0.77)0.0010.25224
ΔFFMI0.01(−0.15, 0.17)0.947
ΔVO2max/FFM−0.08(−0.21, 0.04)0.196
∆Metabolic syndrome scoreΔFMI0.55(0.40, 0.70)<0.0010.39215
ΔFFMI0.08(−0.08, 0.24)0.333
ΔVO2max/FFM−0.09(−0.19, 0.01)0.083
∆Waist-to-height ratioΔFMI0.79(0.68, 0.89)<0.0010.85255
ΔFFMI0.19(0.12, 0.26)<0.001
ΔVO2max/FFM−0.03(−0.12, 0.06)0.458
∆Systolic blood pressureΔFMI0.36(0.15, 0.57)0.0010.13231
ΔFFMI−0.04(−0.23, 0.16)0.718
ΔVO2max/FFM0.04(−0.10, 0.17)0.608
∆Diastolic blood pressureΔFMI0.40(0.20, 0.59)<0.0010.13231
ΔFFMI−0.07(−0.34, 0.20)0.604
ΔVO2max/FFM0.04(−0.10, 0.19)0.554
∆LDLΔFMI0.47(0.28, 0.67)<0.0010.16243
ΔFFMI−0.18(−0.40, 0.04)0.103
ΔVO2max/FFM−0.10(−0.23, 0.03)0.119
∆HDLΔFMI−0.23(−0.60, 0.13)0.2050.14249
ΔFFMI−0.12(−0.30, 0.06)0.197
ΔVO2max/FFM0.13(0.03, 0.24)0.016
∆TriglyceridesΔFMI0.30(−0.03, 0.63)0.0770.11245
ΔFFMI0.02(−0.14, 0.18)0.834
ΔVO2max/FFM−0.04(−0.23, 0.16)0.718
∆Visceral fat volumeΔFMI0.98(0.86, 1.09)<0.0010.8541a
ΔFFMI−0.13(−0.27, 0.04)0.439
ΔVO2max/FFM−0.05(−0.21, 0.13)0.764
∆Liver fat %ΔFMI0.77(0.52, 0.98)<0.0010.5841a
ΔFFMI−0.11(−0.35, 0.17)0.504
ΔVO2max/FFM−0.16(−0.41, 0.12)0.335

Abbreviation: CI, confidence interval.

a

Subjects only from TwinFat. β denotes standardized regression coefficients, which correspond to how many standard deviations the outcome variable will change for an increase in the predictor of 1 standard deviation.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close